comparemela.com

Latest Breaking News On - Research institute translational health science technology - Page 2 : comparemela.com

DGCI nod to Biological E to conduct phase 2/3 clinical trials of its COVID-19 vaccine on children between 5 and 18 years

DGCI nod to Biological E to conduct phase 2/3 clinical trials of its COVID-19 vaccine on children between 5 and 18 years
freepressjournal.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freepressjournal.in Daily Mail and Mail on Sunday newspapers.

Centre finalises deal with Hyderabad-based firm for 30 crore Covid vaccine doses

URL copied Centre finalises advance deal with Hyderabad-based firm for 30 crore Covid vaccine doses The Union Ministry of Health has finalised arrangements with Hyderabad based vaccine manufacturer Biological-E to reserve 30 crore of COVID-19 vaccine doses. These vaccine doses will be manufactured and stockpiled by M/s Biological-E from August-December 2021.  For this purpose, the Union Ministry of Health would be making an advance payment of Rs. 1500 crore to M/s Biological-E.  The COVID-19 vaccine of Biological-E is currently undergoing Phase-3 clinical trial after showing promising results in Phase 1 and 2 clinical trials. The vaccine being developed by Biological-E is a RBD protein sub-unit vaccine and is likely to be available in the next few months. 

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.